Fenoldopam (mesylate) structure
|
Common Name | Fenoldopam (mesylate) | ||
---|---|---|---|---|
CAS Number | 67227-57-0 | Molecular Weight | 401.86 | |
Density | 1.38g/cm3 | Boiling Point | 522.6ºC at 760 mmHg | |
Molecular Formula | C17H20ClNO6S | Melting Point | N/A | |
MSDS | Chinese USA | Flash Point | 269.9ºC | |
Symbol |
GHS07 |
Signal Word | Warning |
Use of Fenoldopam (mesylate)Fenoldopam(SKF 82526) mesylate is a drug and synthetic benzazepine derivative which acts as a selective D1 receptor partial agonist.Target: D1 ReceptorFenoldopam is a selective dopamine-1 (DA1) agonist with natriuretic/diuretic properties. Fenoldopam stimulated cAMP accumulation in LLC-PK1 cells in a dose-dependent manner, an effect which could be blocked by the DA1-selective antagonist Sch 23390. Although fenoldopam was more potent than DA (EC50 55.5 +/- 7.75 nM vs. 1.65 +/- 0.64 microM) in stimulating cAMP accumulation in LLC-PK1 cells, the maximum stimulation obtained by fenoldopam was only 37% of the maximum stimulation obtained by DA(Emax 13.0 +/- 2.95 pmol/mg of protein vs. 35.6 +/- 10.19 pmol/mg of protein) [1]. Fenoldopam is a selective dopamine1 (DA1) receptor agonist. Most of the DA1 receptor agonist activity of fenoldopam resides in the R-enantiomer, which also shows weaker alpha 2-adrenoceptor antagonist activity Fenoldopam produces vasodilation in vascular beds that are rich in vascular DA1 receptors [2]. |
Name | 9-chloro-5-(4-hydroxyphenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diol,methanesulfonic acid |
---|---|
Synonym | More Synonyms |
Description | Fenoldopam(SKF 82526) mesylate is a drug and synthetic benzazepine derivative which acts as a selective D1 receptor partial agonist.Target: D1 ReceptorFenoldopam is a selective dopamine-1 (DA1) agonist with natriuretic/diuretic properties. Fenoldopam stimulated cAMP accumulation in LLC-PK1 cells in a dose-dependent manner, an effect which could be blocked by the DA1-selective antagonist Sch 23390. Although fenoldopam was more potent than DA (EC50 55.5 +/- 7.75 nM vs. 1.65 +/- 0.64 microM) in stimulating cAMP accumulation in LLC-PK1 cells, the maximum stimulation obtained by fenoldopam was only 37% of the maximum stimulation obtained by DA(Emax 13.0 +/- 2.95 pmol/mg of protein vs. 35.6 +/- 10.19 pmol/mg of protein) [1]. Fenoldopam is a selective dopamine1 (DA1) receptor agonist. Most of the DA1 receptor agonist activity of fenoldopam resides in the R-enantiomer, which also shows weaker alpha 2-adrenoceptor antagonist activity Fenoldopam produces vasodilation in vascular beds that are rich in vascular DA1 receptors [2]. |
---|---|
Related Catalog | |
References |
Density | 1.38g/cm3 |
---|---|
Boiling Point | 522.6ºC at 760 mmHg |
Molecular Formula | C17H20ClNO6S |
Molecular Weight | 401.86 |
Flash Point | 269.9ºC |
PSA | 104.24000 |
LogP | 3.77680 |
Storage condition | room temp |
Symbol |
GHS07 |
---|---|
Signal Word | Warning |
Hazard Statements | H302-H317-H319 |
Precautionary Statements | P280-P301 + P312 + P330-P305 + P351 + P338 |
Hazard Codes | Xn |
Risk Phrases | 22-36-42/43 |
Safety Phrases | 22-26-36/37/39 |
RIDADR | NONH for all modes of transport |
~% Fenoldopam (mes... CAS#:67227-57-0 |
Literature: US2006/194967 A1, ; Page/Page column 7-8 ; |
Precursor 2 | |
---|---|
DownStream 0 |
The role of eNOS phosphorylation in causing drug-induced vascular injury.
Toxicol. Pathol. 42(4) , 709-724, (2014) Previously we found that regulation of eNOS is an important part of the pathogenic process of Drug-induced vascular injury (DIVI) for PDE4i. The aims of the current study were to examine the phosphory... |
|
In vitro screening of clinical drugs identifies sensitizers of oncolytic viral therapy in glioblastoma stem-like cells.
Gene Ther. 22 , 947-59, (2015) Oncolytic viruses (OV) have broad potential as an adjuvant for the treatment of solid tumors. The present study addresses the feasibility of clinically applicable drugs to enhance the oncolytic potent... |
|
Contrast-induced nephropathy: protective role of fenoldopam.
Clin. Exp. Pharmacol. Physiol. 39(6) , 497-505, (2012) 1. Contrast-induced nephropathy (CIN) often occurs after contrast media-related procedures and is associated with increased morbidity and mortality. The acute renal failure observed after administrati... |
EINECS 266-612-7 |
Fenoldopam monomethanesulfonate |
MFCD04112986 |
6-Chloro-2,3,4,5-tetrahydro-7,8-dihydroxy-1-(p-hydroxyphenyl)-1H-3-benzazepinium methanesulphonate |
Corlopam |
Fenoldopam methanesulfonate |
6-chloro-2,3,4,5-tetrahydro-1-(4-hydroxyphenyl)-1H-3-benzazepine-7,8-diol methanesulfonate |
9-chloro-5-(4-hydroxyphenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diol |
Fenoldopam mesylate |
6-chloro-7,8-dihydroxy-1-(p-hydroxyphenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine methanesulfonate |
6-chloro-2,3,4,5-tetrahydro-1-(p-hydroxyphenyl)-1H-3-benzazepine-7,8-diol methanesulfonate |
CORLOPAM MESYLATE |
Fenoldopam (mesylate) |